On Wednesday, June 12th, at 10am CDT (8am PDT/9am MDT/11am EDT) AveXis, a Novartis company, and Cure SMA will co-host a webinar on the FDA approval of Zolgensma. This webinar will include information about the approval, dosing sites, future IT clinical trials, and more. The webinar will also include a Q&A session.
Please note that all questions must be submitted at least 24 hours in advance of the webinar. You will be able to submit your questions when you register.
This webinar is intended for U.S. audiences only.